https://www.selleckchem.com/products/VX-770.html
The case-cohort analysis yielded VE estimates of 72% (95% CI 64-79%) for UTD, 39% (95% CI 10-58%) for 2 doses-not UTD, and 48% (95% CI 25-63%) for 1 dose. VE was higher for vaccination at age 20 than greater than or equal to20 years. The statewide registry linkage found significant VE against CIN3+ with incomplete HPV vaccination, and an even higher VE with UTD vaccination. Future VE evaluations by number of doses for women vaccinated at younger ages may further clarify dose-related effectiveness. Future VE evaluations by number of d